<SEC-DOCUMENT>0001104659-24-069785.txt : 20240607
<SEC-HEADER>0001104659-24-069785.hdr.sgml : 20240607
<ACCEPTANCE-DATETIME>20240607192509
ACCESSION NUMBER:		0001104659-24-069785
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240607
FILED AS OF DATE:		20240607
DATE AS OF CHANGE:		20240607

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Glickman Mark A
		CENTRAL INDEX KEY:			0001441461
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		241031166

	MAIL ADDRESS:	
		STREET 1:		C/O ESPERION THERAPEUTICS, INC.
		STREET 2:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2416741-3_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-07</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001638287</issuerCik>
        <issuerName>NeuroBo Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>NRBO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001441461</rptOwnerCik>
            <rptOwnerName>Glickman Mark A</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NEUROBO PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>545 CONCORD AVENUE, SUITE 210</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02138</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-06-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>5051</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>9740</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date.</footnote>
        <footnote id="F2">The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Phillip D. Torrence, by Power of Attorney</signatureName>
        <signatureDate>2024-06-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
